Une pensée économique russe?: présentation, traduction et annotation de l'article "Science Economique" (1899) de Mikhail Ivanovich Tugan-Baranovskij

L'économiste russe Tugan-Baranovskij (1865-1919) a publié en 1899 une notice sur le développement de la « science économique russe » pour la première encyclopédie universelle russe, le Brockhaus-Efron. Sous la forme d'un catalogue chronologique des économistes russes et de leurs ouvrages tout au long du XIXe siècle, le récit de Tugan-Baranovskij représente une des premières tentatives d'écrire une histoire de la pensée économique russe. L'intérêt du texte se manifeste lorsqu'on s'interroge sur l'existence d'une telle science « nationale » de l'économie politique. Nous présentons ici en traduction française ce récit jamais encore traduit du russe, et nous l'accompagnons de notes sur les auteurs et les ouvrages qui y sont signalés.

Long-term outcomes of 118 patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) enrolled in two prospective trials.

The purpose of this study was to assess the outcomes of 118 patients with eosinophilic granulomatosis with polyangiitis (EGPA) enrolled in 2 prospective, randomized, open-label clinical trials (1994-2005), with or without Five-Factor Score (FFS)-defined poor-prognosis factors, focusing on survival, disease-free survival, relapses, clinical and laboratory findings, therapeutic responses, and factors predictive of relapse. Forty-four patients with FFS ≥ 1 were assigned to receive 6 or 12 cyclophosphamide pulses plus corticosteroids and the seventy-four with FFS = 0 received corticosteroids alone, with immunosuppressant adjunction when corticosteroids failed. Patients were followed (2005-2011) under routine clinical care in an extended study and data were recorded prospectively. Mean ± SD follow-up was 81.3 ± 39.6 months. Among the 118 patients studied, 29% achieved long-term remission and 10% died. Among the 115 patients achieving a first remission, 41% experienced ≥1 relapses, 26.1 ± 26.8 months after treatment onset, with 57% of relapses occurring when corticosteroid-tapering reached <10 mg/day. Treatment achieved new remissions in >90%, but relapses recurred in 38%. Overall survival was good, reaching 90% at 7 years, regardless of baseline severity. Age ≥65 years was the only factor associated with a higher risk of death during follow-up. The risk of relapse was higher for patients with anti-myeloperoxidase antibodies and lower for those with >3000 eosinophils/mm(3). Sequelae remained frequent, usually chronic asthma and peripheral neuropathy. In conclusion, EGPA patients' survival rate is very good when treatment is stratified according to the baseline FFS. Relapses are frequent, especially in patients with anti-myeloperoxidase antibodies and baseline eosinophilia <3000/mm(3).